West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.45-3.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.46. The company issued revenue guidance of $1.95-1.97 billion, compared to the consensus revenue estimate of $1.95 billion.West Pharmaceutical Services also updated its FY20 guidance to $3.45-3.55 EPS.
Shares of NYSE WST traded up $0.19 during trading hours on Friday, reaching $174.57. The stock had a trading volume of 391,947 shares, compared to its average volume of 418,727. The company has a current ratio of 3.00, a quick ratio of 2.31 and a debt-to-equity ratio of 0.17. The firm has a market cap of $11.84 billion, a price-to-earnings ratio of 57.24, a P/E/G ratio of 3.31 and a beta of 1.21. The business’s fifty day moving average price is $156.35 and its two-hundred day moving average price is $147.47. West Pharmaceutical Services has a 52-week low of $100.93 and a 52-week high of $175.21.
West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 13th. The medical instruments supplier reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.10. The company had revenue of $470.60 million during the quarter, compared to analyst estimates of $451.53 million. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. West Pharmaceutical Services’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.73 earnings per share. Equities research analysts anticipate that West Pharmaceutical Services will post 3.14 earnings per share for the current fiscal year.
A number of research firms have weighed in on WST. Bank of America lowered West Pharmaceutical Services from a neutral rating to an underperform rating and set a $135.00 target price for the company. in a report on Thursday, December 12th. Zacks Investment Research lowered West Pharmaceutical Services from a buy rating to a hold rating in a report on Friday. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $132.29.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Featured Article: Using other technical indicators with support levels
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.